Page 43 - PCC03

Biomarkers from blood (2)
Nisenblat V et al. Cochrane Database Syst Rev. 2016 May 1;(5):CD012179.
- Meta-analyses could only be performed on the data sets for anti- endometrial antibodies, interleukin-6 (IL-6), cancer antigen-19.9 (CA- 19.9) and CA-125.
- Results:
- anti-endometrial antibodies (4 studies, 759 women) sensitivity
0.81, specificity 0.75.
- IL-6, with a cut-off value of > 1.90 to 2.00 pg/ml (3 studies, 309 women), sensitivity 0.63, specificity 0.69.
- CA-19.9, with a cut-off value of > 37.0 IU/ml (3 studies, 330 women), sensitivity 0.36, specificity 0.87.
- CA-125 was assessed at different concentration ranges, none of which reached the pre-defined criteria for a clinically useful test: (i.e. sensitivity ≥ 94%, specificity ≥ 79%)
- 82 studies evaluated 97 biomarkers that did not differentiate women with endometriosis from disease-free controls.
Non-invasive biomarkers | Prof. Dr. Martin Götte
Biomarkers from blood (3)
Nisenblat V et al. Cochrane Database Syst Rev. 2016 May 1;(5):CD012179.
- Author’s conclusions:
- No marker subjected to meta-analysis consistently met the criteria for
a replacement or triage diagnostic test.
- A subset of blood biomarkers could prove useful either for detecting pelvic endometriosis or for differentiating ovarian endometrioma from other benign ovarian masses, but there was insufficient evidence to draw meaningful conclusions.
- None of the biomarkers displayed enough accuracy to be used clinically outside a research setting.
- Some blood biomarkers demonstrated no diagnostic value in endometriosis, therefore, research resources should be focussed on evaluating other more clinically useful biomarkers.
Non-invasive biomarkers | Prof. Dr. Martin Götte
Page 37 of 55
PRECONGRESS COURSE 03 I BARCELONA, SPAIN – 1 JULY 2018 43